Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 105,947

Document Document Title
WO/2015/043566A1
The invention relates to a peptide comprising at least one peptide which binds to an amyloid-beta species. The peptide has an amino acid sequence which is present in cyclized form. The invention also relates to the use of the peptides in...  
WO/2015/046193A1
The present invention relates to a compound represented by formula (I) (In the formula, R1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclic group, etc., X is -N(R2)-, -O- or -S-, Y...  
WO/2015/044679A1
The invention relates to the finding that turnover of DISC1 (Disrupted in schizophrenia 1) is mediated by the F-box-containing protein FBXW7 (F-box/WD repeat-containing protein 7). The sequence within DISC1 that binds to FBXW7 and target...  
WO/2015/044963A1
The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a proce...  
WO/2015/044270A1
The present invention relates to crystalline and amorphous forms of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-a]pyri dine mono-phosphate salt and methods of making these solid forms thereof. The invention compounds are modula...  
WO/2015/043111A1
The present invention relates to field of pharmaceutical chemistry, and specifically relates to a new type of benzazepine ketone derivatives (I), a preparation method therefor, and medical uses thereof. The present type of compounds can ...  
WO/2015/043522A1
The present invention relates to trifluoromethyl-containing amide alkaloid, a manufacturing method thereof, pharmaceutical combinations containing same, and pharmaceutical use thereof. The trifluoromethyl-containing amide alkaloid of the...  
WO/2015/044462A1
The present invention concerns a neuroglobin agonist for use in the treatment or prevention of a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and/or respiratory chain complex III (RCCIII) deficiency.  
WO/2015/042281A1
The present invention is based, at least in part, on the discovery that fragments of the histone deacetylase 4 (HDAC4) gene lacking the enzymatic domain promoted rod survival when electroporated into the retinas of a relevant mouse model...  
WO/2015/042580A1
Disclosed are methods of treating neuropathic pain in a human subject by administering a neublastin polypeptide at a dosage of 100-1,600 μg/kg body weight of the human subject.  
WO/2015/041544A1
This invention relates to compositions comprising bee venom and an extract of a plant of the genus Capsicum, such as Capsicum annuum, and their uses for ameliorating the symptoms of arthritis, joint pain, muscle pain, sports injury, mult...  
WO/2015/039758A1
The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compou...  
WO/2015/042243A1
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various diso...  
WO/2015/039619A1
Use of a traditional Chinese medicine composition in preparation of medicine for treating Alzheimer's disease (senile dementia). The traditional Chinese medicine composition is prepared from Radix Angelicae Sinensis 6.75%, Rhizoma Chuanx...  
WO/2015/039244A1
A system for obtaining and analyzing data for overall joint motion from a plurality of joints of a subject experiencing a movement disorder involves a plurality of kinematic sensors configured to be placed on a body of a subject experien...  
WO/2015/039587A1
The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in...  
WO/2015/040613A1
Provided herein are compositions, methods of use thereof and kits comprising same for prophylaxis, alleviating or treating a subject with, or experiencing symptoms associated with, attention deficit disorder/attention deficit hyperactivi...  
WO/2015/039212A1
Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or dis...  
WO/2015/040151A1
The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes p...  
WO/2015/037716A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, R1 is an optionally substituted C1-4 alkyl, n is an integer of 1 to 4, R2 is an optionally substituted C...  
WO/2015/036972A2
Working memory deficits are treated and working memory is improved with a composition that comprises a therapeutically effective amount of one or more respective selective dopamine D4 receptor agonists and/or pharmaceutically acceptable ...  
WO/2015/037019A3
The present invention relates to modified release compositions comprising plurality of modified release units. Particularly, the modified release units comprise at least one anti-Alzheimer's agent, at least one ion exchange resin and at ...  
WO/2015/036734A1
The present invention relates a pharmaceutical composition comprising (a) an opioid analgesic drug and/or an enkephalinase inhibitor, and (b) a selective Nav1.7 inhibitor.  
WO/2015/035500A1
Described is the use of L-tryptophan for treating a subject with parasomnia and associated methods of treating a subject with parasomnia. Optionally, the subject may be a child or adolescent between about 3 years of age and 18 years of a...  
WO/2015/036370A1
The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation...  
WO/2015/036412A1
The present invention relates to compounds of general formula (I) wherein R1 is aryl or heteroaryl, which are optionally substituted by one, two or three substituents, selected from lower alkyl, halogen, lower alkyl substituted by haloge...  
WO/2015/035460A1
An antisense oligonucleotide of 10 to 50 nucleotides comprising a targeting sequence complementary to a region near or within intron 6, intron 7, or exon 8 of the Survival Motor Neuron 2 (SMN2) gene pre-mRNA.  
WO/2015/036009A1
The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologicaiiy acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation...  
WO/2015/038778A1
This disclosure relates to substituted urea eIF2α kinase activators including methods of making and using the same. For example, such activators can include cycloalkyl aryl ureas, which activate at least one eIF2α kinase. These compoun...  
WO/2015/037248A1
Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(-)-ke...  
WO/2015/037587A1
This method of producing 4-(((6S,9S)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(qu inoline-8-ylmethyl) octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-6-yl)methyl) phenyl dihydrogen phosphate involves a step for adding a reaction solution...  
WO/2015/036646A1
HSPs (chaperones or heat-shock proteins) possess two very valuable characteristics that can be productively exploited in a specific form in order to "intelligently" manipulate the immune response so as to treat "conformational" disorders...  
WO/2015/038112A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2015/037656A1
 Autophagy-regulating miRNA molecules according to the present invention are formed from base sequences represented by any of SEQ ID NO: 1-203 in the sequence listing. These miRNA molecules were identified using an miRNA screening meth...  
WO/2015/037659A1
 An aqueous solution formulation containing compound (I) can be manufactured by performing the following steps: a first step in which a solution is prepared by dissolving, in an organic solvent, a compound represented by formula (I) or...  
WO/2015/035802A1
The present invention relates to novel vortioxetine salt, a solvate and a crystal form thereof, specifically, vortioxetine hemi-hydrobromide and a crystal form thereof, and a vortioxetine hydrobromide isopropanol solvate and a crystal fo...  
WO/2015/038938A1
Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modi...  
WO/2015/036618A1
The present invention relates to a compound which is an antagonist of the GluK2/GluK5 receptor or an inhibitor of the GluK2/GluK5 receptor expression for use in the treatment or the prevention of epilepsy.  
WO/2015/033267A1
The present invention relates to the diagnostic and therapeutic uses of Arpin, a protein from the Uncharacterized Protein Family UPF0552, which is a new inhibitor of the Arp2/3 that inhibits cell migration and is associated with the prog...  
WO/2015/033175A1
Combination of endogenous pro-opiomelanocortin peptides is combination of the adrenocorticotropic hormone ACTH 1-13 and metenkefalin. The invention is a therapy to substitute corticosteroids, in the disease relapse and at determining the...  
WO/2015/035117A1
Pyrazolo[1,5-a]pyrimidine-based compounds of the formula (I) are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders m...  
WO/2015/035184A1
Disclosed herein are crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate. Crystalline form 1, Crystalline form 2, Crystalline 3, and Crystalline form 4 are dis...  
WO/2015/035414A1
The invention relates to methods for treating neurological disorders by targeting the elimination of selective peripherally activated immune cell populations. The cells may be targeted, for instance, using CLIP inhibitors.  
WO/2015/032328A1
The present invention relates to an indane derivative, a preparation method therefor, and a pharmaceutical application thereof. Specifically, the present invention relates to a compound shown in formula (I), or a stereoisomer thereof, an...  
WO/2015/032233A1
Disclosed in the present invention is the use of a recombinant Lingzhi mushroom immunomodulatory protein (rLZ_8) expressed by Pichia pastoris in the preparation of drugs for treating focal cerebral ischemia. rLZ_8 is able to treat neurol...  
WO/2015/032519A1
Specific mixtures comprising one or more (cannabinoid) compounds of the formula (A) and/or one or more of the salts thereof are described, as are processes for preparation thereof. Also described are a compound of the formula (A), a salt...  
WO/2015/035167A1
Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders media...  
WO/2015/034012A1
Provided is a method for manufacturing dopamine-producing neural precursor cells from pluripotent stem cells, the method comprising: (i) a step in which pluripotent stem cells are cultured adherently on an extracellular matrix in a cultu...  
WO/2015/032272A1
The present invention relates to a C-aryl glucoside derivative, a preparation method for same, and medical applications thereof. Specifically, the present invention relates to compounds as represented by formula I, and, tautomers, enanti...  
WO/2015/032966A1
The disclosure relates to thecompound2-(cyclohexylmethyl)-N-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline- 7-sulfonamideor a pharmaceutically acceptable salt thereof, intended forthe treatment of Alzheimer's dis...  

Matches 251 - 300 out of 105,947